Literature DB >> 16368966

The CC chemokine receptor 5 is important in control of parasite replication and acute cardiac inflammation following infection with Trypanosoma cruzi.

Jenny L Hardison1, Ruth A Wrightsman, Philip M Carpenter, William A Kuziel, Thomas E Lane, Jerry E Manning.   

Abstract

Infection of susceptible mice with the Colombiana strain of Trypanosoma cruzi results in an orchestrated expression of chemokines and chemokine receptors within the heart that coincides with parasite burden and cellular infiltration. CC chemokine receptor 5 (CCR5) is prominently expressed during both acute and chronic disease, suggesting a role in regulating leukocyte trafficking and accumulation within the heart following T. cruzi infection. To better understand the functional role of CCR5 and its ligands with regard to both host defense and/or disease, CCR5(-/-) mice were infected with T. cruzi, and the disease severity was evaluated. Infected CCR5(-/-) mice develop significantly higher levels of parasitemia (P < or = 0.05) and cardiac parasitism (P < or = 0.01) during acute infection that correlated with reduced survival. Further, we show that CCR5 is essential for directing the migration of macrophages and T cells to the heart early in acute infection with T. cruzi. In addition, data are provided demonstrating that CCR5 does not play an essential role in maintaining inflammation in the heart during chronic infection. Collectively, these studies clearly demonstrate that CCR5 contributes to the control of parasite replication and the development of a protective immune response during acute infection but does not ultimately participate in maintaining a chronic inflammatory response within the heart.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16368966      PMCID: PMC1346647          DOI: 10.1128/IAI.74.1.135-143.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  50 in total

Review 1.  Chemokines and chemokine receptors in leukocyte trafficking.

Authors:  Timothy S Olson; Klaus Ley
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-07       Impact factor: 3.619

2.  Functional expression of chemokine receptor CCR5 on CD4(+) T cells during virus-induced central nervous system disease.

Authors:  William G Glass; Thomas E Lane
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

4.  Intracellular growth of Trypanosoma cruzi in cardiac myocytes is inhibited by cytokine-induced nitric oxide release.

Authors:  Laura Edith Fichera; Maria Cecilia Albareda; Susana Adriana Laucella; Miriam Postan
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  Regulated on activation, normal T cell expressed and secreted (RANTES) antagonist (Met-RANTES) controls the early phase of Trypanosoma cruzi-elicited myocarditis.

Authors:  Ana Paula M P Marino; Andréa da Silva; Paula dos Santos; Luzia Maria de Oliveira Pinto; Ricardo Tostes Gazzinelli; Mauro Martins Teixeira; Joseli Lannes-Vieira
Journal:  Circulation       Date:  2004-08-30       Impact factor: 29.690

6.  Involvement of the chemokine RANTES (CCL5) in resistance to experimental infection with Leishmania major.

Authors:  Helton da Costa Santiago; Carolina Ferreira Oliveira; Luciana Santiago; Fernanda Oliveira Ferraz; Daniele da Glória de Souza; Luiz Antônio Rodrigues de-Freitas; Luís Carlos Crocco Afonso; Mauro Martins Teixeira; Ricardo Tostes Gazzinelli; Leda Quercia Vieira
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

Review 7.  Mouse hepatitis virus infection of the central nervous system: chemokine-mediated regulation of host defense and disease.

Authors:  William G Glass; Benjamin P Chen; Michael T Liu; Thomas E Lane
Journal:  Viral Immunol       Date:  2002       Impact factor: 2.257

8.  Genetic control of responses to Trypanosoma cruzi in mice: multiple genes influencing parasitemia and survival.

Authors:  R Wrightsman; S Krassner; J Watson
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

9.  Studies of Trypanosoma cruzi clones in inbred mice. I. A comparison of the course of infection of C3H/HEN- mice with two clones isolated from a common source.

Authors:  M Postan; J A Dvorak; J P McDaniel
Journal:  Am J Trop Med Hyg       Date:  1983-05       Impact factor: 2.345

10.  Functional analysis of the CC chemokine receptor 5 (CCR5) on virus-specific CD8+ T cells following coronavirus infection of the central nervous system.

Authors:  William G Glass; Thomas E Lane
Journal:  Virology       Date:  2003-08-01       Impact factor: 3.616

View more
  30 in total

1.  Role of CCL3/MIP-1alpha and CCL5/RANTES during acute Trypanosoma cruzi infection in rats.

Authors:  Ester Roffê; Fabiano Oliveira; Adriano L S Souza; Vanessa Pinho; Danielle G Souza; Patrícia R S Souza; Remo C Russo; Helton C Santiago; Alvaro J Romanha; Herbert B Tanowitz; Jesus G Valenzuela; Mauro M Teixeira
Journal:  Microbes Infect       Date:  2010-05-07       Impact factor: 2.700

2.  The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi.

Authors:  Jenny L Hardison; Ruth A Wrightsman; Philip M Carpenter; Thomas E Lane; Jerry E Manning
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation.

Authors:  Nicole L Sullivan; Christopher S Eickhoff; Xiuli Zhang; Olivia K Giddings; Thomas E Lane; Daniel F Hoft
Journal:  J Immunol       Date:  2011-06-29       Impact factor: 5.422

4.  Increased brain damage after ischaemic stroke in mice lacking the chemokine receptor CCR5.

Authors:  S Sorce; J Bonnefont; S Julien; N Marq-Lin; I Rodriguez; M Dubois-Dauphin; K H Krause
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

5.  Enalapril in Combination with Benznidazole Reduces Cardiac Inflammation and Creatine Kinases in Mice Chronically Infected with Trypanosoma cruzi.

Authors:  Arlete Rita Penitente; Ana Luísa Junqueira Leite; Guilherme de Paula Costa; Deena Shrestha; Aline Luciano Horta; Antônio J Natali; Clóvis A Neves; Andre Talvani
Journal:  Am J Trop Med Hyg       Date:  2015-09-08       Impact factor: 2.345

6.  Macrophage migration inhibitory factor contributes to host defense against acute Trypanosoma cruzi infection.

Authors:  José L Reyes; Luis I Terrazas; Bertha Espinoza; David Cruz-Robles; Virgilia Soto; Irma Rivera-Montoya; Lorena Gómez-García; Heidi Snider; Abhay R Satoskar; Miriam Rodríguez-Sosa
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

7.  Therapy with recombinant T-cell receptor ligand reduces infarct size and infiltrating inflammatory cells in brain after middle cerebral artery occlusion in mice.

Authors:  Suzan Dziennis; Sarah Mader; Kozaburo Akiyoshi; Xuefang Ren; Patricia Ayala; Gregory G Burrows; Arthur A Vandenbark; Paco S Herson; Patricia D Hurn; Halina A Offner
Journal:  Metab Brain Dis       Date:  2011-04-07       Impact factor: 3.584

Review 8.  Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease.

Authors:  Fabiana S Machado; Walderez O Dutra; Lisia Esper; Kenneth J Gollob; Mauro M Teixeira; Stephen M Factor; Louis M Weiss; Fnu Nagajyothi; Herbert B Tanowitz; Nisha J Garg
Journal:  Semin Immunopathol       Date:  2012-10-18       Impact factor: 9.623

Review 9.  Restriction of the felid lentiviruses by a synthetic feline TRIM5-CypA fusion.

Authors:  Isabelle Dietrich; William A McEwan; Margaret J Hosie; Brian J Willett
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

10.  Pathogenesis of Chagas disease: time to move on.

Authors:  Fabiana S Machado; Kevin M Tyler; Fatima Brant; Lisia Esper; Mauro M Teixeira; Herbert B Tanowitz
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.